Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

Autologous stem cell transplantation (ASCT) is a standard treatment for eligible multiple myeloma (MM) patients, but many patients will relapse after ASCT and require subsequent therapy. The proteasome inhibitor carfilzomib is approved for relapsed or refractory MM (RRMM). In phase 3 trials, carfilz...

Descripción completa

Detalles Bibliográficos
Autores principales: Hari, P, Mateos, M-V, Abonour, R, Knop, S, Bensinger, W, Ludwig, H, Song, K, Hajek, R, Moreau, P, Siegel, D S, Feng, S, Obreja, M, Aggarwal, S K, Iskander, K, Goldschmidt, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729352/
https://www.ncbi.nlm.nih.gov/pubmed/28439109
http://dx.doi.org/10.1038/leu.2017.122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729352/
https://www.ncbi.nlm.nih.gov/pubmed/28439109
http://dx.doi.org/10.1038/leu.2017.122

Ejemplares similares